New Insights on Fak and Fak Inhibitors

被引：17

作者：

Brullo, Chiara ^{[1
]}

Tasso, Bruno ^{[1
]}

机构：

[1] Univ Genoa, Dept Pharm, Viale Benedetto XV 3, I-16132 Genoa, Italy

来源：

CURRENT MEDICINAL CHEMISTRY | 2021年 / 28卷 / 17期

关键词：

Focal adhesion kinase; Fak inhibitors; metastasis; cancer therapy; clinical trials; PROTACS; FOCAL-ADHESION KINASE; NUCLEAR FAK; SELECTIVE INHIBITOR; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; ENDOTHELIAL FAK; CANCER; PYK2; PATHWAYS; ANTITUMOR;

D O I：

10.2174/0929867327666201103162239

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Background: Focal adhesion kinase (Fak) is a cytoplasmic protein tyrosine ki-nase overexpressed and activated in different solid cancers; it has shown an important role in metastasis formation, cell migration, invasion and angiogenesis and consequently it has been proposed as a potential target in cancer therapy, particularly in a metastatic phase. In recent years, different investigations have highlighted the importance of new Fak inhibitors as potential anti-cancer drugs, but other studies evidenced its role in different pathologies related to the cardiac function or viral infection. Methods: An extensive bibliographic research (104 references) has been done concerning the structure of Fak, its importance in tumor development, but also in other pathologies currently under study. The compounds currently subjected to clinical studies were therefore treated using the appropriate databases. Finally, the main chemical scaffolds currently under preclinical investigation were analyzed, focusing on their molecular structures and on the activity structure relationships (SAR). Results: At the moment, only a few reversible ATP-competitive inhibitors are under investigation in pre-clinical studies and clinical trials. Other compounds, with different chemical scaffolds, are investigated to obtain more active and selective Fak inhibitors. This mini-review is a summary of different Fak functions in cancer and other pathologies; the compounds today in clinical trials and the recent chemical scaffolds (also included in patents) giving the most interesting results are investigated. In addition, PROTAC molecules are reported. Conclusion: All reported results evidenced that additional studies are necessary to design and synthesize new selective and more active compounds, although promising information has been obtained from associations between Fak inhibitors and other different anti-cancer drugs. In addition, the other important roles evidenced, both at the nuclear level and in non-cancerous cells, make this protein an increasingly important target in pharmaceutical chemistry. <comment>Superscript/Subscript Available</comment

引用

页码：3318 / 3338

页数：21

共 123 条

[1]

Adams J.L., 2009, Anilinopyridines as inhibitors of Fa k, Patent No. [WO 2009105498, 2009105498]

[2] Design and synthesis of diphenylpyrimidine derivatives (DPPYs) as potential dual EGFR T790M and FAK inhibitors against a diverse range of cancer cell lines [J].

Ai, Min ;

Wang, Changyuan ;

Tang, Zeyao ;

Liu, Kexin ;

Sun, Xiuli ;

Ma, Tengyue ;

Li, Yanxia ;

Ma, Xiaodong ;

Li, Lei ;

Chen, Lixue .

BIOORGANIC CHEMISTRY, 2020, 94

[3]

Alaoui-Jamali M.A., 2013, Compounds targeting the cell invasion protein complex, their pharmaceutical compositions and methods of use thereof, Patent No. [WO 2013059927, 2013059927]

[4] The Focal Adhesion Kinase Inhibitor GSK2256098: a Potent and Selective Inhibitor for the Treatment of Cancer [J].

Auger, K. R. ;

Smitheman, K. N. ;

Korenchuk, S. ;

McHugh, C. ;

Kruger, R. ;

Van Aller, G. S. ;

Smallwood, A. ;

Gontarek, R. R. ;

Faitg, T. ;

Johnson, N. .

EUROPEAN JOURNAL OF CANCER, 2012, 48 :118-118

[5] RAFTK/Pyk2-mediated cellular signalling [J].

Avraham, H ;

Park, SY ;

Schinkmann, K ;

Avraham, S .

CELLULAR SIGNALLING, 2000, 12 (03) :123-133

[6] Down-Regulation of DDR1 Induces Apoptosis and Inhibits EMT through Phosphorylation of Pyk2/MKK7 in DU-145 and Lncap-FGC Prostate Cancer Cell Lines [J].

Azizi, Reza ;

Fallahian, Faranak ;

Aghaei, Mahmoud ;

Salemi, Zahra .

ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2020, 20 (08) :1009-1016

[7] Integrated genomic analyses of ovarian carcinoma [J].

Bell, D. ;

Berchuck, A. ;

Birrer, M. ;

Chien, J. ;

Cramer, D. W. ;

Dao, F. ;

Dhir, R. ;

DiSaia, P. ;

Gabra, H. ;

Glenn, P. ;

Godwin, A. K. ;

Gross, J. ;

Hartmann, L. ;

Huang, M. ;

Huntsman, D. G. ;

Iacocca, M. ;

Imielinski, M. ;

Kalloger, S. ;

Karlan, B. Y. ;

Levine, D. A. ;

Mills, G. B. ;

Morrison, C. ;

Mutch, D. ;

Olvera, N. ;

Orsulic, S. ;

Park, K. ;

Petrelli, N. ;

Rabeno, B. ;

Rader, J. S. ;

Sikic, B. I. ;

Smith-McCune, K. ;

Sood, A. K. ;

Bowtell, D. ;

Penny, R. ;

Testa, J. R. ;

Chang, K. ;

Dinh, H. H. ;

Drummond, J. A. ;

Fowler, G. ;

Gunaratne, P. ;

Hawes, A. C. ;

Kovar, C. L. ;

Lewis, L. R. ;

Morgan, M. B. ;

Newsham, I. F. ;

Santibanez, J. ;

Reid, J. G. ;

Trevino, L. R. ;

Wu, Y. -Q. ;

Wang, M. .

NATURE, 2011, 474 (7353) :609-615

[8] Targeting the proviral host kinase, FAK, limits influenza a virus pathogenesis and NFkB-regulated pro-inflammatory responses [J].

Bergmann, Silke ;

Elbahesh, Husni .

VIROLOGY, 2019, 534 :54-63

[9]

Breslin H. J., 2012, Macrocyclic compounds as ALK, Fa k and Ja k 2 inhibitors and their preparation and use for the treatment of ALK-Fa k-and Ja k 2-mediated diseases, Patent No. [WO 2012125603, 2012125603]

[10] A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098 [J].

Brown, Nicholas F. ;

Williams, Matthew ;

Arkenau, Hendrik-Tobias ;

Fleming, Ronald A. ;

Tolson, Jerry ;

Yan, Li ;

Zhang, Jianping ;

Swartz, Lisa ;

Singh, Rajendra ;

Auger, Kurt R. ;

Lenox, Laurie ;

Cox, David ;

Lewis, Yvonne ;

Plisson, Christophe ;

Searle, Graham ;

Saleem, Azeem ;

Blagden, Sarah ;

Mulholland, Paul .

NEURO-ONCOLOGY, 2018, 20 (12) :1634-1642

← 1 2 3 4 5 6 7 8 9 10 →